[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myopic-astigmatism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myopic-astigmatism":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100621965","a-study-to-investigate-the-safety-and-effectiveness-of-the-technolas-teneo-317-model-2-excimer-laser-for-laser-in-situ-keratomileusis-lasik-surgery-to-treat-myopia-or-myopic-astigmatism-100621965",false,"NCT07377474","A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism","A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism With Sphere Between 0.00D and -1.00D","Inclusion Criteria:\n\n1. Are 22 years of age or older.\n2. Have read, understood, and signed an ICF.\n3. Have demonstrated stable refraction (i.e., a change of ≤ ± 0.5 D in sphere and cylinder) for a minimum of 12 months prior to surgery verified by consecutive refractions, medical records or prescription history.\n4. Have myopic refractive error with or without astigmatism; sphere 0.00 D up to -1.00 D, cylinder between 0.00 D and -3.00 D; with a manifest refraction spherical equivalent (MRSE) between -.0375 D and -2.50 D.\n5. Wears distance correction or has a need for distance correction.\n6. Have manifest, distance best spectacle corrected visual acuity (BSCVA) of 20\u002F25 (logMAR 0.1) or better in an operative eye.\n7. Have equal to or less than 0.50 D spherical equivalent (SE) difference between cycloplegic and manifest refractions at Visit 1 (Pre-operative).\n8. Have normal corneal topography as determined by the Investigator.\n9. Anticipated postoperative stromal thickness of at least 350 microns.\n10. Have discontinued use of contact lenses for at least 2 weeks (for hard or toric lenses) or 3 days (for soft contact lenses) prior to the pre-operative examination, and through the day of surgery.\n11. All contact lens wearers must demonstrate a stable refraction (within ± 0.5 D), as determined by MRSE, on two consecutive examinations at least 1 week apart, in an eye to be treated and the axis of cylinder should not differ by more than 15 degrees from the baseline cycloplegic refraction.\n12. Agree to emmetropia correction for each treated eye\n13. Have the ability to lie flat without difficulty.\n14. Are willing and able to comply with the schedule for all post-surgery follow-up visits.\n\nExclusion Criteria:\n\n1. Subjects for whom the combination of their baseline corneal thickness and the planned operative parameters for the LASIK procedure would result in treatment depth less than 250 microns from corneal endothelium.\n2. Acute or chronic disease or illness that would increase operative risk or confound the results of the study (e.g., dry eye, cataract, immuno-compromise, rheumatoid arthritis, clinically significant atopic disease, acne rosacea, autoimmune disease, endocrine disorders, lupus, systemic connective tissue disease, diabetes, or severe atopic disease).\n3. Ocular conditions that may predispose the subject to future complications, including but not limited to:\n\n   * History or evidence of retinal vascular disease\n   * History or evidence of active corneal disease or infection (e.g., recurrent corneal erosion syndrome, herpes simplex or herpes zoster keratitis) in either eye.\n   * History of or evidence of glaucoma or glaucoma suspect (e.g., IOP \\> 21 mmHg).\n4. Eyes for which the baseline manifest subjective refraction exhibits a difference greater than 0.50 D in sphere power, or a difference greater than 0.50 D in cylinder power, or a difference in cylinder axis of more than 15 degrees compared to the baseline cycloplegic subjective refraction. For manifest cylinder of less than 0.50 D, the difference in cylinder axis will not be taken into consideration.\n5. Subjects for whom the pre-operative assessment of the cornea indicates that one or both eyes are not suitable candidates for treatment based upon the Investigator's medical judgment.\n6. Have evidence of retinal vascular disease.\n7. Have a history of or have active corneal disease or infection (e.g., recurrent corneal erosion syndrome, herpes simplex or herpes zoster keratitis, etc.) in either eye.\n8. Have a known sensitivity to any study medication.\n9. Have central corneal scars affecting visual acuity or unstable keratometry with irregular mires in an eye considered for eligibility.\n10. Presence of keratoconus, subclinical or forme fruste keratoconus, corneal dystrophy, unstable central keratometry readings with irregular mires, or other corneal irregularity (e.g., irregular astigmatism).\n11. Had previous intraocular or corneal surgery in an eye considered for eligibility that might confound the outcome of the study or increase the risk to the subject.\n12. Use chronic medications by any administration route that may increase risk to the subject or may confound the outcome of the study, including those known to affect wound healing (e.g., corticosteroids, antimetabolites, etc.).\n13. Are taking medications contraindicated with LASIK such as isotretinoin (Accutane) or amiodarone hydrochloride (Cordarone).\n14. Are known to be pregnant, lactating, or who plan to become pregnant during the course of the study.\n15. Have known sensitivity to medications used for standard LASIK.\n16. Have the presence of systemic disease likely to affect wound healing, e.g., autoimmune disease, systemic connective tissue disease, diabetes, or severe atopic disease.\n17. Are participating in any other ophthalmic clinical trial within 30 days of screening or during this clinical trial.\n18. Have an ocular muscle disorder including a strabismus or nystagmus, or other disorder affecting fixation.\n19. Have a history of or evidence of glaucoma or are a glaucoma suspect.\n20. Eyes with mesopic pupil size \\> 7.0 mm.\n21. Have a Schirmer's pre-operative test without anesthesia \\\u003C 4 mm\u002F5 minutes","ALL","22 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"NA","This will be a multicenter, prospective, open label, non-randomized, single arm study evaluating the safety and effectiveness of the Technolas® TENEO 317 Model 2 (version 1.28 US software) Excimer Laser when used in LASIK surgery to treat myopia or myopic astigmatism. One or both eyes of a subject may be treated so long as both eyes meet all inclusion\u002Fexclusion requirements.",[26],"Myopic Astigmatism","NOT_YET_RECRUITING","2026-01-26",{"date":30,"type":31},"2026-01-30","ACTUAL",{"date":33,"type":20},"2026-04",{"date":35,"type":20},"2027-09",{"name":37,"class":38},"Bausch & Lomb Incorporated","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100596627","a-clinical-trial-assessing-the-safety-and-effectiveness-of-orthokeratology-lenses-in-patients-with-myopia-and-myopic-astigmatism-100596627","NCT07047924","A Clinical Trial Assessing the Safety and Effectiveness of Orthokeratology Lenses in Patients With Myopia and Myopic Astigmatism","A Prospective, Multi-centre, Single-Arm Clinical Trial of Orthokeratology Lenses (MCOK-01) in Subjects With Myopia and Myopic Astigmatism","SEMOA","Inclusion Criteria:\n\n1. Participant diagnosed with myopia and myopic astigmatism, documented by an eye care practitioner.\n2. Participant is between 6-40 years old inclusive.\n3. Participant is not motivated to wear glasses in daily life.\n4. Participants are of Caucasian ethnicity (must be \\>50% of study population) or other non-east Asian ethnic groups (Indian, Sri-Lankan, Pakistani, etc). Neither parent of participant can be east-asian.\n5. Provision of written informed consent.\n6. Participants understand and agree to all requirements of the clinical trial; visit schedule, investigator guidance, follow-lens instructions, etc\n\nExclusion Criteria:\n\n1. Best corrected distance vision acuity of less than 0.8 with spectacles.\n2. Subjective refraction test shows spherical power greater than -6.00D,less than -0.50D or astigmatism greater than 1.5D.\n3. Participants of East-Asian ethnicity (Chinese, Japanese, Korean, etc).\n4. Participants requiring treatment for eye disease other than refractive error (excluding those receiving artificial tears eye drops due to the wearing of corneal contact lenses).\n5. Medical history of intraocular surgery that may affect the effect of wearing the lens for this clinical trial (those with corneal transplantation, Retinal detachment, etc)..\n6. Medical history of refractive corneal surgery.\n7. Slit lamp findings that are more serious than grade 1\n8. Participants requiring lens parameters outside of the scope of lens for this clinical trial.\n9. Known eye allergies or conditions that are contraindicated, including sensitivity to any lens care maintenance or packaging solution additives being used in this study\n10. Corneal abnormalities including keratoconus, corneal dystrophy and\u002For previous history of ocular herpes infections.\n11. Currently using Atropine, or have used Atropine eye drops 14 days prior to enrolment.\n12. For female participants, pregnancy, planned pregnancy during the trial or breastfeeding (pregnancy status provided by verbal confirmation).\n13. Participation in other clinical trials or participation within the past 30 days.\n14. Use of orthokeratology lenses within the prior 90 days, extended wear, rigid gas permeable corneal and scleral lenses within the prior 30 days, daily disposable and daily wear within the prior 15 days.\n15. Mental incapacity.\n16. Other Participants deemed not suitable for the trial at the investigator's discretion","6 Years","40 Years",{"count":50,"type":20},220,[23],"This is a prospective, multi-centre, single-arm clinical trial to evaluate the effectiveness and safety of MCOK-01 lenses in patients with myopia and myopic astigmatism who need dioptric correction.\n\nA maximum number of 220 participants are planned to be enrolled , with a minimum of 150 planned to complete the trial (30% dropout). All participants will be enrolled in Australia.\n\nEnrolled participants will wear the lenses every night for up to 12 months, removing them upon waking. 8 follow up visits will be completed during treatment, after: 1 day, 1 week, 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months of wearing the lenses.",[54,26],"Myopia",[54,26,56,57],"Orthokeratology Lenses","Orthokeratology","2025-06-24",{"date":60,"type":31},"2025-07-02",{"date":62,"type":20},"2025-07-01",{"date":64,"type":20},"2026-12-01",{"name":66,"class":38},"Menicon Co., Ltd.",4,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":67},"100580638","a-prospective-randomized-clinical-study-of-two-phakic-toric-implantable-lenses-100580638","NCT06839898","A Prospective, Randomized Clinical Study of Two Phakic Toric Implantable Lenses","A Prospective, Randomized Clinical Study of Two Phakic Toric Implantable Lenses to Compare Outcomes in Patients With Moderate to High Myopia and Astigmatism","Inclusion Criteria:\n\n* Patients 21 years old or older.\n* Calculated IOL Power is within the range of the investigational IOLs\n* Corneal Cylindrical error within the range defined in the clinical investigation plan\n* Subject has monocular UCVA 0.5 LogMAR or worse\n* Subject has had a stable refraction (±0.5D; ±1.0D for higher refractive errors), as expressed by manifest refraction spherical equivalent (MRSE) for a minimum 12 months prior to surgery, verified by consecutive refractions and\u002For medical records or prescription history.\n* Subject, who is a current contact lens wearer, needs to demonstrate a stable refraction (±0.5D) expressed as MRSE, on two consecutive examination dates and stability of the refraction is determined by the following criteria:\n\n  1. Contact lenses were not worn for at least 2 weeks or 3 days prior to the first refraction.\n  2. Two refractions were performed at least 7 days apart.\n* Subject, who is expected to have residual postoperative cylindrical refractive error of ≥1D, has been given the opportunity to experience his\u002Fher best spectacle vision with the anticipated correction.\n* Expected dilated pupil size at least large enough to visualize the axis marking.\n* Patients willing to attend all follow-up appointments\n* Patients must sign and be given a copy of the written Informed Consent form\n\nExclusion Criteria:\n\n* Subject with acute and chronic disease or illness that would increase the operative risk or confound the outcomes of the evaluation.\n* Subject taking systematic medication that can confound the outcome of the study or increase the risk to the subject\n* Subject with ocular condition that may predispose the subject to future complications\n* Subject with previous intraocular or corneal surgery\n* Subject with less than the minimum endothelial cell density 2000 cells\u002Fmm² at the time of enrollment\n* Pregnant or planning to become pregnant, or is lactating during the course of the evaluation\n* Other condition associated with fluctuation of hormones\n* ACD measured from the endothelium lower than 2.8 mm\n* Concurrent participation in another drug or device evaluation.\n* Any cataract of any grade.\n* Coefficient of variation of endothelial cell area \\>0.45\n* Percent Hexagonality of endothelial cell shape ≤ 45%\n* Monocular subject\n* Vulnerable subjects as defined in section 12.3.10","21 Years",{"count":77,"type":20},172,[23],"Primary Objective: To compare the efficacy and the residual refractive error of EYECRYLTM Phakic toric versus Visian® Toric ICL in moderate to high myopic patient with co-existing astigmatism. Secondary Objectives: To evaluate and compare the safety of EYECRYLTM Phakic toric versus Visian® Toric ICL in moderate to high myopic patients with co-existing astigmatism.",[81,26,82],"Myopia, Moderate","Myopia, Degenerative","RECRUITING","2025-02-17",{"date":86,"type":31},"2025-02-21",{"date":88,"type":31},"2021-10-10",{"date":90,"type":20},"2027-02",{"name":92,"class":38},"Biotech Healthcare Holding Gmbh"]